|
Rudolf Fahrig
Prof. Dr.rer.nat.habil |
CEO
Founder of RESprotect GmbH, Inventor of RP101 |
Geneticist, responsible for business and science. Conception and design of in vivo-screening systems and clinical studies. |
|
Klaus Kutz
Prof. Dr. med. |
CMO
Clinical Studies |
Physician, long-time experience as Head of Clinical Pharmacology in two internationally operating pharmaceutical companies. |
|
Jörg-Christian Heinrich
Dr.rer.nat. |
CSO
Cell and Molecular Biology |
Biologist, preclinical development of the drugs of the second generation. Elucidation of the mode of action of RP101 and 2nd generation substances. |
|
Andreas Koch
Dr.-Ing. |
Director
Chemistry and Pharmacy |
Chemist, long-time experience in chemical syntheses. Preparation of drug master files, FDA and EMEA approvals. |
